Lipogen is expanding its production facilities and building a new phospholipids research and development (R&D) center in response to radocusate and ferrous fumaratepid, 50% jump in sales of brain and stress health solutions in Q1-Q3 2015.###The company invested US$2.6 million in building two additional production lines for PhosphatidylSerine (PS) and Phosphatidic Acid (PA).###It also added 10,000 sq ft to its facilities to double production capabilities for PS and PA.###Upgrades include automated controlled processing to reduce production costs through improved production traceability, and implementing new safety methods, allowing Lipogen to produce its all-natural, non-genetically modified organism, solvent-free ingredients in accordance with the highest industry standards.###The PS market is forecast to grow significantly due to developments of new applicatiosolgar zinc citrate 30 mgns and a growing demand in emerging markets, such as India and China.###Data from Nutrition Business Journal put the US cognitive health market at US$1.2 billion by 2014, up from under US$1 billion in 2010.###It estimates the market will hit almost US$1.5 billion by 2020.###“Increasing demfergon 325and for our brain health and stress maliquid calcium citratenagement ingredients pushed us to establish a new growth strategy for our PS and PA product line,” says CEO David Rutenberg.###&#8220calcium magnesium citrate with vitamin d3;The phospholipids market is expanding from traditional brain function support to new brain health concepts, including: stress management, cortisol control, ADHD [attention deficit hyperactivity disorder] mitigation and sports nutrition.”###